![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1628124
½ÉÀå Æó¼â ±â±â ½ÃÀå : ½ÃÀå ±âȸ, ¼ºÀå ÃËÁø¿äÀÎ, »ê¾÷ µ¿Ç⠺м®, ¿¹Ãø(2025-2034³â)Heart Closure Devices Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034 |
2024³â¿¡ 40¾ï ´Þ·¯·Î Æò°¡µÈ ¼¼°èÀÇ ½ÉÀå Æó¼â ±â±â ½ÃÀåÀº 2025³âºÎÅÍ 2034³â±îÁö CAGR 15.9%ÀÇ °ßÁ¶ÇÑ ¼ºÀåÀÌ Àü¸ÁµÇ°í ÀÖ½À´Ï´Ù.
ÀÌ ¼ºÀåÀÇ ¹è°æÀ¸·Î´Â ½ÉÇ÷°ü ÁúȯÀÇ À¯º´·ü »ó½Â, Àúħ½À Ä¡·á·ÎÀÇ Àüȯ, »óȯ Á¤Ã¥ÀÇ °³¼± µîÀÌ ÀÖ½À´Ï´Ù.
½ÉÇ÷°ü Áúȯ(CVDs)Àº ¿©ÀüÈ÷ ¼¼°è °Ç° ¹®Á¦ÀÇ Áß½ÉÀÌ¸ç ¸Å³â ¼ö¹é¸¸ ¸íÀÇ »ç¸Á¿¡ ±â¿©ÇÕ´Ï´Ù. Àα¸ÀÇ °í·ÉÈ, ¶óÀÌÇÁ½ºÅ¸Àϰú °ü·ÃµÈ À§Çè¿äÀÎ Áõ°¡, ¾É¾Æ Àֱ⸸ ÇÏ´Â »ýȰ µîÀÌ ½ÉÀå Æó¼â ±â±â ¼ö¿ä¸¦ ²ø¾î¿Ã¸®°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â±¸´Â ½ÉÀå °áÇÔÀ» È¿°úÀûÀ¸·Î Ä¡·áÇÏ´Â µ¥ ÇʼöÀûÀ̸ç, ħ½À¼ºÀÌ ³·±â ¶§¹®¿¡ ¸¹Àº ȯÀÚ¿¡°Ô ÀÌ»óÀûÀÎ ¼Ö·ç¼ÇÀ¸·Î °£Áֵ˴ϴÙ.
½ÉÀå Æó¼â ±â±â ¼ö¿ä¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ´Â °ÍÀº Á¾·¡ÀÇ ¼ö¼úÀ» ´ë½ÅÇÏ´Â Àúħ½ÀÀÇ ´ëü ¼ö´ÜÀ» Á¦°øÇÒ ¼ö ÀÖ´Ù´Â °ÍÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ±â±¸´Â ÀϹÝÀûÀ¸·Î Ä«Å×Å͸¦ »ç¿ëÇÏ´Â ÀýÂ÷¿¡ ÀÇÇØ »ðÀԵǸç, Á¾·¡ÀÇ °³½É¼ú¿¡ ºñÇØ ȯÀÚ´Â ´õ ÀûÀº ÅëÁõ°ú ÀûÀº ÀÔ¿ø ±â°£¿¡ ´õ »¡¸® ȸº¹µÉ ¼ö ÀÖ½À´Ï´Ù. ȯÀÚ¿Í ÀÇ·á ¼ºñ½º Á¦°ø¾÷ü°¡ ħ½À Ä¡·á¸¦ ¼±ÅÃÇÏ´Â °æÇâÀÌ Ä¿Áö°í ÀÖ´Â µ¿¾È ½ÉÀå Æó¼â ±â±â ½ÃÀåÀº ²ÙÁØÈ÷ ¼ºÀåÇϰí ÀÖ½À´Ï´Ù.
½ÃÀå ¹üÀ§ | |
---|---|
½ÃÀÛ³â | 2024³â |
¿¹Ãø ¿¬µµ | 2025-2034³â |
½ÃÀÛ ±Ý¾× | 40¾ï ´Þ·¯ |
¿¹Ãø ±Ý¾× | 177¾ï ´Þ·¯ |
CAGR | 15.9% |
½ÉÀå Æó¼â ±â±â´Â ½ÉÀåÀÇ ºñÁ¤»óÀûÀÎ °³±¸ºÎ, ƯÈ÷ ¼±Ãµ¼º ÁúȯÀÎ ½É¹æ Áß°Ý °á¼Õ ¹× ½É½Ç Áß°Ý °á¼ÕÀ» Æó¼âÇϴµ¥ »ç¿ëµË´Ï´Ù. ÀÌ·¯ÇÑ °áÇÔÀº ½É¹æ »çÀÌÀÇ ÀǵµÇÏÁö ¾ÊÀº Ç÷·ù¸¦ À¯¹ßÇÕ´Ï´Ù. Á¦Ç° À¯Çüº°·Î, ½ÃÀåÀº ÁÂ½É¹æ ºÎ¼Ó±â(LAA) Æó¼â ±â±â, ½É¹æ Áß°Ý °á¼Õ(ASD) Æó¼â ±â±â, ½É½Ç Áß°Ý °á¼Õ(VSD) Æó¼â ±â±â, ³¿ø°ø °³Á¸(PFO) Æó¼â ±â±â µîÀÇ ¹üÁÖ·Î ³ª´µ¸ç, LAA ±â±â´Â ±× ¸¹Àº ÀåÁ¡À¸·ÎºÎÅÍ ½ÃÀåÀ» ¼±µµÇϰí ÀÖ½À´Ï´Ù.
LAA Æó¼â ±â±â´Â ³úÁ¹Áß À§ÇèÀ» ÁÙÀ̴µ¥ ƯÈ÷ È¿°úÀûÀ̸ç ÇÕº´ÁõÀ» ÀÏÀ¸Å³ ¼ö ÀÖ´Â Àå±â Ç×ÀÀ°í ¿ä¹ýÀ» ´ëüÇÒ ¼ö ÀÖ´Â ¿É¼ÇÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ±â±â´Â ÇÕº´Áõ ¹ß»ý·üÀÌ ³·°í ȸº¹ÀÌ ºü¸£¸ç ÀÔ¿ø ±â°£ÀÌ ´ÜÃàµÇ¹Ç·Î Á¡Á¡ ¼±È£µÇ°í ÀÖÀ¸¸ç ä¿ë·üÀÌ »ó½ÂÇϰí ÀÖ½À´Ï´Ù. ±â¼úÀÇ Áøº¸¿Í ÀÎÁöµµÀÇ Çâ»óµµ LAA ±â±âÀÇ »ç¿ë È®´ë¸¦ µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù.
Àç·áº°·Î´Â ´ÏƼ³îÀ» º£À̽º·Î ÇÑ ½ÉÀå Æó¼â ±â±â°¡, ÃÊź¼ºÀ¸·Î »ýü ÀûÇÕ¼ºÀÌ ¶Ù¾î³ª±â ¶§¹®¿¡ ½ÃÀåÀÇ ¼ºÀåÀ» ¸®µåÇÒ °ÍÀ¸·Î ¿¹»óµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â±â´Â ħ½À¼ºÀÌ ³·Àº ÀýÂ÷¸¦ À§ÇØ Ä«Å×ÅÍ·Î ¾ÐÃàµÇ¾î ½ÉÀåÀÇ µ¿Àû Èû ÇÏ¿¡¼µµ Àß ÀÛµ¿ÇϹǷΠȯÀÚÀÇ Àå±âÀûÀÎ ¾ÈÀüÀ» º¸ÀåÇÕ´Ï´Ù. ½Å·ÚÇÒ ¼ö ÀÖ´Â ½ÉÇ÷°ü ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¿ä±¸°¡ Áõ°¡ÇÔ¿¡ µû¶ó ÀÌ·¯ÇÑ ±â±â¿¡ ´ëÇÑ ¼ö¿ä°¡ ´Ã¾î³ª°í ÀÖÀ¸¸ç, ½ÃÀåÀº 2034³â±îÁö 92¾ï ´Þ·¯ ÀÌ»ó¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
±âÁ¸ÀÇ ¼ö¼úº¸´Ù ħ½À¼ºÀÌ ³·Àº °æ Ä«Å×ÅÍ Àü´Þ ¹æ¹ýµµ ½ÉÀå Æó¼â ±â±â ½ÃÀåÀÇ ÁÖ¿ä ¼ºÀå ¿äÀÎÀÔ´Ï´Ù. °æ Ä«Å×ÅÍ ¼ö¼úÀº ȯÀÚÀÇ ÇÕº´ÁõÀÌ Àû°í ȸº¹ÀÌ ºü¸£±â ¶§¹®¿¡ °Ç° °ü¸® Á¦°ø¾÷ü¿Í ȯÀÚ ¸ðµÎ¿¡¼ ÀαâÀÖ´Â ¼±ÅÃÀÌ µÇ¾ú½À´Ï´Ù. Æ®·£½ºÄ«Å×ÅÍ ±â¼úÀÇ °³¼±ÀÌ ÁøÇàµÊ¿¡ µû¶ó ÀÌ·¯ÇÑ ±â±â ½ÃÀå Á¡À¯À²ÀÌ Å©°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÃÖÁ¾ ¿ëµµÀÇ °æ¿ì º¹ÀâÇÑ ½ÉÀå Æó¼â ÀýÂ÷¸¦ ´Ù·ç´Â °í±Þ ¼³ºñ¿Í Àü¹® Áö½ÄÀ¸·Î º´¿øÀÌ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù. ¼÷·ÃµÈ ÀÇ·á Àü¹®°¡°¡ Á¸ÀçÇÔÀ¸·Î½á ȯÀÚ´Â ÃÖ°í ¼öÁØÀÇ Ä¡·á¸¦ ¹ÞÀ» ¼ö ÀÖÀ¸¸ç º´¿ø ½ÃÀå ¸®´õ½ÊÀº ´õ¿í °ÈµË´Ï´Ù.
ºÏ¹Ì´Â ¼¼°èÀÇ ½ÉÀå Æó¼â ±â±â ½ÃÀåÀ» ¼±µµÇϰí ÀÖÀ¸¸ç, 2025³âºÎÅÍ 2034³â±îÁöÀÇ CAGRÀº 14.3%·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀÇ Çõ½Å ±â¼úÀÇ Á¶±â µµÀÔÀº À¯¸®ÇÑ »óȯ Á¤Ã¥°ú ¿¬±¸¿¡ ´ëÇÑ ¸¹Àº ÅõÀÚ¿Í ÇÔ²² ½ÉÀå Æó¼â ±â±â ½ÃÀåÀÇ ¿ìÀ§¸¦ ´õ¿í µÞ¹ÞħÇÕ´Ï´Ù.
The Global Heart Closure Devices Market, valued at USD 4 billion in 2024, is expected to grow at a robust CAGR of 15.9% from 2025 to 2034. This growth can be attributed to the rising prevalence of cardiovascular diseases, a shift towards minimally invasive procedures, and improved reimbursement policies, among other factors.
Cardiovascular diseases (CVDs) remain a leading global health issue, contributing to millions of deaths annually. The aging population, increasing lifestyle-related risk factors, and sedentary living have propelled the demand for heart closure devices. These devices are becoming essential in treating heart defects effectively and are seen as an ideal solution for many patients due to their minimally invasive nature.
The demand for heart closure devices is fueled by their ability to offer a less invasive alternative to traditional surgeries. These devices are typically inserted via catheter-based procedures and allow patients to recover faster with less pain and fewer hospital stays compared to conventional open-heart surgeries. As patients and healthcare providers increasingly opt for minimally invasive treatments, the heart closure devices market is growing steadily.
Market Scope | |
---|---|
Start Year | 2024 |
Forecast Year | 2025-2034 |
Start Value | $4 Billion |
Forecast Value | $17.7 Billion |
CAGR | 15.9% |
Heart closure devices are used to close abnormal heart openings, particularly atrial and ventricular septal defects, which are congenital conditions. These defects cause unintended blood flow between the heart's chambers. In terms of product type, the market is divided into categories such as left atrial appendage (LAA) closure devices, atrial septal defect (ASD) closure devices, ventricular septal defect (VSD) closure devices, and patent foramen ovale (PFO) closure devices, with LAA devices leading the market due to their numerous benefits.
LAA closure devices are particularly effective in reducing stroke risk and offer an alternative to long-term anticoagulant therapy, which can cause complications. These devices are increasingly preferred for their low complication rates, faster recovery, and reduced hospital stays, leading to a higher adoption rate. Technological advances and increased awareness are also driving the growing use of LAA devices.
In terms of material, nitinol-based heart closure devices are expected to lead market growth, owing to their superelasticity and excellent biocompatibility. These devices are compressed into catheters for less invasive procedures and perform well under the dynamic forces within the heart, ensuring long-term patient safety. The growing need for reliable cardiovascular solutions is driving the demand for these devices, with the market projected to reach over USD 9.2 billion by 2034.
The transcatheter delivery method, which is less invasive than traditional surgery, is another key growth driver in the heart closure devices market. With transcatheter procedures, patients experience fewer complications and a faster recovery time, making it a popular choice among both healthcare providers and patients. As transcatheter technologies continue to improve, the market share for these devices is expected to grow significantly.
In terms of end-use, hospitals dominate the market due to their advanced facilities and expertise in handling complex heart closure procedures. The presence of skilled medical professionals ensures that patients receive the highest standard of care, further reinforcing hospitals' market leadership.
North America leads the global market for heart closure devices, with a projected CAGR of 14.3% from 2025 to 2034. The region's early adoption of innovative technologies, coupled with favorable reimbursement policies and substantial investments in research, further supports its dominance in the heart closure devices market.